Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline
Purpose Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly developing, painful ulcers. This study explores the potential of spesolimab, an anti-IL-36R antibody, as a therapeutic option for refractory PG.Materials and methods We report a case of a 48-year-old male w...
Saved in:
Main Authors: | Hanlin Zhang, Chao Wu, Hongzhong Jin |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2451811 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid
by: Kyohei Shibuta, et al.
Published: (2025-01-01) -
PASS Syndrome: Clinical Observation
by: Olga Valentinovna Grabovskaya, et al.
Published: (2025-01-01) -
Crusted Scabies in a Patient being Treated with Spesolimab for Generalized Pustular Psoriasis
by: Hanna Schratter, et al.
Published: (2025-02-01) -
Intralesional Spesolimab: A Novel and Effective Approach for Palmoplantar Pustulosis Treatment – A Case Report
by: Wang SN, et al.
Published: (2025-01-01) -
Effectiveness and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Single-centre Retrospective Study
by: Yoshiki Okada, et al.
Published: (2025-02-01)